Skip to main content

Advertisement

SpringerLink
Log in

Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Surgery and chemotherapy are the standard of care for epithelial ovarian cancer, and it is well established that survival outcomes are improved when the surgery results in no or optimal (less than 1 cm) residual disease. However, for patients with bulky disease that may require extensive or radical procedures to accomplish this goal, the use of neoadjuvant chemotherapy followed by interval debulking surgery to simplify the surgery and minimize morbidity has been suggested. Arguably, this is only ideal if this process produces survival outcomes equivalent to those of primary debulking surgery. The purpose of this article is to review the data surrounding this controversial topic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cancer Facts & Figures. (2014). Atlanta: American Cancer Society; 2014.

  2. Buys, S.S., Partridge, E., Black, A., Johnson, C.C., Lamerato, I., Isaacs, C. (2011). Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. Journal of the American Medical Association. 2295–303.

  3. Menon, U.G-M.A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., Lewis, S., Davies, S., Philpott, S., Lopes, A., Godfrey, K., Oram, D., Herod, J., Williamson, K., Seif, MW., Scott, I., Mould, T., Woolas, R., Murdoch, J., Dobbs, S., Amso, NN., Leeson, S., Cruickshank, D., et al. (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology. 327–40.

  4. Kurman, R.J., Shih, I.M. (2011). Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Human Pathology. 918–31.

  5. Griffiths, C. (1975). Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. National Cancer Institute Monographs. 101–4.

  6. Hoskins, W. J., Bundy, B. N., Thigpen, J. T., & Omura, G. A. (1992). The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study. Gynecologic Oncology, 47(2), 159–62.

    Article  CAS  PubMed  Google Scholar 

  7. Hoskins, W.J., Creasman, M.W., Grady, M.F., Homesley, H.D., Creasman, W.T., Berman, M., Ball, H., Berek, J.S. (1994). The effect of tumor diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology. 974–9.

  8. Fader, A. N., & Rose, P. (2007). Role of surgery in ovarian carcinoma. Journal of Clinical Oncology, 25(20), 2873–83.

    Article  PubMed  Google Scholar 

  9. Bristow, R. E., Tomacruz, R., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology, 20(5), 1248–59.

    Article  PubMed  Google Scholar 

  10. Chang, S. J., Bristow, R., & Ryu, H. S. (2012). Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in ovarian cancer. Annals of Surgical Oncology, 19, 4059–67.

    Article  PubMed  Google Scholar 

  11. Winter, W. E., Maxwell, G., Tian, C., Carlson, J. W., Ozols, R. F., Rose, P. G., Markman, M., Armstrong, D. K., Muggia, F., & McGuire, W. P. (2007). Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology study group. Journal of Clincial Oncology, 25(24), 3621–7.

    Article  Google Scholar 

  12. du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., & Pfisterer, J. (2009). Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer, 115, 1234–44.

    Article  PubMed  Google Scholar 

  13. Elattar, A., Bryant, A., Winter-Roach, B.A., Hatem, M., Naik, R. (2011). Optimal primary surgical treatment for advanced epithelial ovarian cancer (Review). Cochrane Database Systematic Review. 2011.

  14. Vergote, I. B., De Wever, I., Decloedt, J., Tjalma, W., Van Gramberen, M., & van Dam, P. (2000). Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Seminars in Oncology, 27(3 Suppl 7), 31–6.

    CAS  PubMed  Google Scholar 

  15. Schwartz, P. E., Chambers, J. T., & Makuch, R. (1994). Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology, 53(1), 33–7.

    Article  CAS  PubMed  Google Scholar 

  16. Bristow, R., & Chi, D. S. (2006). Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecologic Oncology, 103, 1070–6.

    Article  CAS  PubMed  Google Scholar 

  17. Schorge, J. O., Clark, R., Lee, S. I., & Penson, R. T. (2014). Primary debulking surgery for advanced ovarian cancer: are you a believer or dissenter? Gynecologic Oncology. doi:10.1016/j.ygyno.2014.10.007.

    Google Scholar 

  18. Aletti, G. D., Dowdy, S., Gostout, B. S., Jones, M. B., Stanhope, C. R., Wilson, T. O., Podratz, K. C., & Kliby, W. A. (2006). Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology, 107(1), 77–85.

    Article  PubMed  Google Scholar 

  19. Vergote, I. T. C., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H., van der Burg, M., Lacave, A. J., Panici, P. B., Kenter, G. G., Casado, A., Mendiola, C., Coens, C., Verleye, L., Stuart, G., Pecorelli, S., & Reed, N. (2010). Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine, 363(10), 943–53.

    Article  CAS  PubMed  Google Scholar 

  20. McGuire, W. P., Hoskins, W., Brady, M. F., Kugera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. New England Journal of Medicine, 334(1), 1–6.

    Article  CAS  PubMed  Google Scholar 

  21. Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine, 354, 34–43.

    Article  CAS  PubMed  Google Scholar 

  22. Chi, D. S., Musa, F., Dao, F., Zivanovic, O., Sonoda, Y., Leitao, M., Levine, D., Gardner, G., Abu-Rustum, N., & Barakat, R. (2012). An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecologic Oncology, 124, 10–4.

    Article  PubMed  Google Scholar 

  23. Kehoe, S., Hook, J., Nankivell, M., et al. (2013). Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial.; 2013; Chicago: 2013 ASCO Annual Meeting, Abstract 5500.

  24. Aletti, G. D., Gostout, B., Podratz, K. C., & Cliby, W. A. (2006). Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecologic Oncology, 100, 33–7.

    Article  PubMed  Google Scholar 

  25. Eisenkop, S. M., & Spirtos, N. (2001). Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival? Gynecologic Oncology, 82, 435–41.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Karmanos Cancer Center, Wayne State University School of Medicine, Detroit, MI, USA

    Shelly M. Seward & Ira Winer

Authors
  1. Shelly M. Seward
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ira Winer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shelly M. Seward.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seward, S.M., Winer, I. Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Cancer Metastasis Rev 34, 5–10 (2015). https://doi.org/10.1007/s10555-014-9536-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-014-9536-y

Keywords

Search

Navigation